A E Czeizel1, M Rockenbauer. 1. Department of Human Genetics and Teratology, National Institute of Hygiene--World Health Organization Collaborating Centre for the Community Control of Hereditary Diseases, Budapest, Hungary.
Abstract
OBJECTIVE: To study the human teratogenic risk of doxycycline treatment during pregnancy. METHODS: Paired analysis of cases with congenital abnormalities and matched healthy controls was performed in the large population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1992. RESULTS: Of 32,804 pregnant women who had infants with no defects in the study period (control group), 63 (0.19%) were treated with doxycycline. Of 18,515 pregnant women who had offspring with congenital abnormalities, 56 (0.30%) were treated with doxycycline, a rate that is higher than that of the control group (P = .01). However, the case-control pair analysis did not show a significantly higher rate of doxycycline treatment in the second and third months of gestation in any group of congenital abnormalities. CONCLUSIONS: Treatment with doxycycline during pregnancy presents very little if any teratogenic risk to the fetus. Thus, if doxycycline treatment is necessary during pregnancy, there would appear to be no contraindication.
OBJECTIVE: To study the human teratogenic risk of doxycycline treatment during pregnancy. METHODS: Paired analysis of cases with congenital abnormalities and matched healthy controls was performed in the large population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1992. RESULTS: Of 32,804 pregnant women who had infants with no defects in the study period (control group), 63 (0.19%) were treated with doxycycline. Of 18,515 pregnant women who had offspring with congenital abnormalities, 56 (0.30%) were treated with doxycycline, a rate that is higher than that of the control group (P = .01). However, the case-control pair analysis did not show a significantly higher rate of doxycycline treatment in the second and third months of gestation in any group of congenital abnormalities. CONCLUSIONS: Treatment with doxycycline during pregnancy presents very little if any teratogenic risk to the fetus. Thus, if doxycycline treatment is necessary during pregnancy, there would appear to be no contraindication.
Authors: Rose McGready; John Antony Jude Prakash; Santosh Joseph Benjamin; Wanitda Watthanaworawit; Tippawan Anantatat; Ampai Tanganuchitcharnchai; Clare L Ling; Saw Oo Tan; Elizabeth A Ashley; Mupawjay Pimanpanarak; Stuart D Blacksell; Nicholas P Day; Pratap Singhasivanon; Nicholas J White; François Nosten; Daniel H Paris Journal: PLoS Negl Trop Dis Date: 2014-11-20
Authors: Irene A Stafford; Kelsey Hummel; James J Dunn; Kenneth Muldrew; Alexandra Berra; Elizabeth Skye Kravitz; Soumya Gogia; Irene Martin; Erik Munson Journal: BMJ Open Date: 2021-06-14 Impact factor: 2.692
Authors: Ghaith Aljayyoussi; Hayley E Tyrer; Louise Ford; Hanna Sjoberg; Nicolas Pionnier; David Waterhouse; Jill Davies; Joanne Gamble; Haelly Metuge; Darren A N Cook; Andrew Steven; Raman Sharma; Ana F Guimaraes; Rachel H Clare; Andrew Cassidy; Kelly L Johnston; Laura Myhill; Laura Hayward; Samuel Wanji; Joseph D Turner; Mark J Taylor; Stephen A Ward Journal: Sci Rep Date: 2017-03-16 Impact factor: 4.379